HPR16 Comparison of Outcomes-Based Reimbursement (OBR) Schemes in Europe and the US for CAR-T Cell Therapy: Tisagenlecleucel
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1148
https://www.valueinhealthjournal.com/article/S1098-3015(22)03353-8/fulltext
Title :
HPR16 Comparison of Outcomes-Based Reimbursement (OBR) Schemes in Europe and the US for CAR-T Cell Therapy: Tisagenlecleucel
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03353-8&doi=10.1016/j.jval.2022.09.1148
First page :
Section Title :
Open access? :
No
Section Order :
10697